Welcome to LookChem.com Sign In|Join Free
  • or

302962-49-8

Post Buying Request

302962-49-8 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
CML Treatment 99%min Dasatinib Manufacturer 302962-49-8
Cas No: 302962-49-8
No Data 10 Gram 10000 Metric Ton/Month Hubei XinRunde Chemical Co., Ltd Contact Supplier
Dasatinib
Cas No: 302962-49-8
No Data No Data No Data Avanscure lifesciences (Shanghai ) Pvt Ltd. Contact Supplier
Dasatinib
Cas No: 302962-49-8
No Data No Data 20 Kilogram/Month ningbo easun bio-tech co., ltd Contact Supplier
Dasatinib
Cas No: 302962-49-8
No Data No Data No Data Shang Hai Grade Biochemical Co,. Limited Contact Supplier
High quality Dasatinib
Cas No: 302962-49-8
USD $ 1.0-1.0 / Kilogram 10 Kilogram 50 Metric Ton/Day Hubei Jusheng Technology Co., Ltd., Contact Supplier
Dasatinib
Cas No: 302962-49-8
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier
Factory supply high quality dasatinib with best price
Cas No: 302962-49-8
No Data No Data 1000 Metric Ton/Month Crovell Biotech (Hebei) Co., Ltd. Contact Supplier
Treatment 99%min Dasatinib Manufacturer 302962-49-8
Cas No: 302962-49-8
USD $ 1.0-3.0 / Metric Ton 1 Metric Ton 10 Metric Ton/Day Hebei yanxi chemical co.,LTD. Contact Supplier
Dasatinib
Cas No: 302962-49-8
USD $ 1.0-1.0 / Metric Ton 1 Metric Ton 200 Metric Ton/Year Henan Sinotech Import&Export Corporation Contact Supplier
Dasatinib
Cas No: 302962-49-8
USD $ 500.0-500.0 / Gram 1000 Gram 100 Kilogram/Day Chengdu Yanxi Import & Export Trading CO.,LTD Contact Supplier

302962-49-8 Usage

Uses

Directly targets wild-type and mutant c-Abl kinase domains

Leukemia drug

Dasatinib is an oral potent oncogenic kinase inhibitor, which can block signal of cancer cell replication acceleration , in May 2009, the US Food and Drug Administration (FDA) formally approved the sale of dasatinib , It has been clinically used for the treatment of various chronic myeloid leukemia (CML), including treatment of chronic myeloid leukemia which is resistant or intolerant to the treating programs including imatinib mesylate., Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) and the treatment of patients with solid tumors.
October 28, 2010 ,the FDA approved dasatinib (Sprycel) of the new indication which is used for the treatment of the rare leukemia first diagnosed Philadelphia chromosome-positive called chronic myeloid leukemia (Ph + CP-CML) . The disease is a blood and bone marrow disease associated with genetic abnormality .
An open-label randomized clinical trial conducted in patients with CP-CML evaluated the safety and efficacy of dasatinib . Common side effects include decreased activity of the bone marrow caused by red blood cells, white blood cells and platelets decreased (myelosuppression), fluid retention, diarrhea, headache, musculoskeletal pain, and rash.
October 11, 2011, the US Food and Drug Administration (FDA) said the leukemia drug dasatinib (Sprycel, Bristol-Myers Squibb Company) might increase pulmonary arterial hypertension (PAH) risk. Pulmonary hypertension is a rare but serious disease that can lead to the condition that heart pumping blood to the lungs becomes more difficult by raising the pressure . PAH symptoms include shortness of breath, fatigue, swelling of the legs and ankles, clinicians must differentiate these symptoms from other similar symptoms.
Since 2006 Dasatinib was approved in the US market ,there had been 12 associated pulmonary hypertension events ,pulmonary hypertension symptoms included shortness of breath, fatigue, hypoxia and fluid retention, patients then were confirmed pulmonary hypertension by the results of right heart catheterization ,studies have shown that the biggest cause of the disease may come from patients taking dasatinib.
The above information is edited by the Chemicalbook of Tian Ye.

Chemical properties

White solid

Chemical Properties

Pale-Yellow Solid

Uses

Suitable for treatment of chronic myeloid leukemia which is resistant or intolerant to the treating programs including imatinib mesylate.

Uses

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

Brand name

Sprycel (Bristol-Myers Squibb).

Uses

A new, oral, small-molecule Tyrosine Kinase Inhibitor (TKI) for the treatment of CML. Antineoplastic

302962-49-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name Dasatinib

1.2 Other means of identification

Product number -
Other names Dasatinib Tablets

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:302962-49-8 SDS

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields